JUV 112
Alternative Names: JUV-112Latest Information Update: 05 Jun 2024
At a glance
- Originator Juvena Therapeutics
- Class Obesity therapies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Obesity
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 05 Jun 2024 Preclinical trials in Obesity in USA (unspecified route), prior to June 2024 (Juvena Therapeutics pipeline, June 2024)
- 18 Oct 2023 JUV 112 is available for licensing as of 18 Oct 2023. https://www.juvenatherapeutics.com/our-science/
- 18 Oct 2023 Juvena Therapeutics has patent pending for drug discovery and development platform in USA, prior to October2 2023 (Juvena Therapeutics pipeline, October 2023)